Pituitary Microadenoma Treated with Antipsychotic Drug Aripiprazole

被引:3
|
作者
Wix-Ramos, Richard J. [1 ,3 ]
Paez, Reinalis [1 ,3 ]
Capote, Eduardo [2 ,3 ]
Ezequiel, Uribe [1 ,3 ]
机构
[1] Univ Carabobo, Fac Ciencias Salud, Dept Ciencias Fisiol, Valencia, Venezuela
[2] Univ Carabobo, Fac Ciencias Polit & Jurid, Valencia, Venezuela
[3] Hosp Psiquiatr Dr Jose Ortega Duran, INSALUD, Valencia, Venezuela
关键词
Aripiprazole; haloperidol; hormonal alteration; pituitary microadenoma syndrome; prolactin; psychosis;
D O I
10.2174/187221411794351905
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Male patient 24 years old with a pituitary microadenoma and mental and behavioural disorders due to multiple drug use and use of other psychoactive substances (cocaine, cannabis and alcohol) were treated with haloperidol (dopamine receptor blocker) 10 mg daily. In the last control, the patient presented mammary hypertrophy; laboratory testing and brain magnetic resonance imaging (MRI) was performed, reporting the presence of a pituitary microadenoma syndrome with hormonal alteration (Prolactin levels 28.4 ng/ml). Haloperidol, carbamazepine and levomepromazine were then discontinued. He was started on aripiprazole 15 mg po daily for 4 days; the dosage was then increased to 30 mg po daily, with Valproic Acid 500 mg po tid. After 3 weeks on aripiprazole, the mammary hypertrophy that had increased in the patient had resolved. After 10 weeks follow up of prolactin revealed a normal level, at 4.33 ng/ml. Insomnia, aggressiveness, irritability, visual, tactile and auditory hallucinations remained absent after treatment with aripiprazole which is not a first line drug in multiple drug use patient with psychosis. We also consider the correlation of drug use in patient with psychosis, haloperidol treatment, pituitary microadenoma syndrome, hyperprolactinemia, and dopamine D2-receptor partial agonist aripiprazole treatment. This article also summarizes some relevant patents.
引用
收藏
页码:58 / 60
页数:3
相关论文
共 50 条
  • [31] MOSAIC TURNERS SYNDROME AND PITUITARY MICROADENOMA
    GASPAR, L
    JULESZ, J
    KOCSIS, J
    PASZTOR, E
    LASZLO, F
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY, 1985, 86 (01): : 87 - 92
  • [32] Suspected olfactory meningioma and synchronous pituitary microadenoma in a canine patient treated with radiation therapy
    Isabelle F. Vanhaezebrouck
    Carlos R. Mendez Valenzuela
    R. Timothy Bentley
    Matthew L. Scarpelli
    Jeanna Blake
    Kari Ekenstedt
    Veterinary Oncology, 1 (1):
  • [33] Prolactine-secreting pituitary microadenoma
    Merran, S
    PRESSE MEDICALE, 1997, 26 (07): : 348 - 348
  • [34] Anejaculation as the presenting feature of pituitary microadenoma
    Nair, Sasha
    Milsom, Stella
    FERTILITY AND STERILITY, 2008, 90 (05) : 2012.e21 - 2012.e23
  • [35] Radiology rounds - Pituitary microadenoma (prolactinoma)
    McLennan, MK
    CANADIAN FAMILY PHYSICIAN, 1998, 44 : 2389 - +
  • [36] PITUITARY MICROADENOMA IN TURNERS-SYNDROME
    PEJAVER, RK
    WATSON, AH
    BRITISH JOURNAL OF CLINICAL PRACTICE, 1995, 49 (04): : 223 - 224
  • [37] PITUITARY MICROADENOMA PRESENTING AS PANIC ATTACKS
    WILCOX, JA
    BRITISH JOURNAL OF PSYCHIATRY, 1991, 158 : 426 - 427
  • [38] Pituitary microadenoma with hypopituitarism presenting as hyponatremia
    Manappallil, Robin George
    Veetil, Pradeep Puthen
    Babu, Harish
    Khan, Sadab Raza
    BMJ CASE REPORTS, 2021, 14 (08)
  • [39] Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy
    Sugai, Takuro
    Suzuki, Yutaro
    Yamazaki, Manabu
    Sugawara, Norio
    Yasui-Furukori, Norio
    Shimoda, Kazutaka
    Mori, Takao
    Ozeki, Yuji
    Matsuda, Hiroshi
    Okamoto, Kurefu
    Sagae, Toyoaki
    Someya, Toshiyuki
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (01) : 14 - 17
  • [40] Stability of Solvates and Packing Systematics of Nine Crystal Forms of the Antipsychotic Drug Aripiprazole
    Braun, Doris E.
    Gelbrich, Thomas
    Kahlenberg, Volker
    Tessadri, Richard
    Wieser, Josef
    Griesser, Ulrich J.
    CRYSTAL GROWTH & DESIGN, 2009, 9 (02) : 1054 - 1065